Vivos Therapeutics

FDA Clearance And New Deployments Will Expand Non-Invasive Sleep Care

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

15 Apr 25

Updated

21 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-55.1%

You can edit this narrative until Nov 22 2:15 AM. Then, changes will post as Updates.

Author's Valuation

US$5.8364.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on 21 Nov 25

Fair value Increased 14%

VVOS: Significant Clinical Findings Will Drive Upside in 2024

Analysts have raised their price target for Vivos Therapeutics from $5.10 to $5.83 per share. They cited improved revenue growth projections and modest adjustments to future profitability assumptions.

Shared on 22 Aug 25

Fair value Increased 21%

The sharp upward revision in the analyst price target for Vivos Therapeutics reflects markedly improved revenue growth forecasts and a lower future P/E multiple, raising fair value from $4.22 to $5.10. What's in the News Vivos Therapeutics will be unable to file its next 10-Q by the SEC deadline.

Shared on 01 May 25

Fair value Decreased 23%

Shared on 24 Apr 25

Fair value Decreased 5.96%

AnalystConsensusTarget has decreased revenue growth from 22.2% to 17.5%.

AnalystConsensusTarget Fair Value

US$5.83

64.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

42.66%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.10%

Calculation

US$4.99m

Earnings '28

22.24x

PE Ratio '28

US$110.89m

Market Cap '28

US$110.89m

Market Cap '28

15.53m

No. shares '28

US$7.14

Share Price '28

US$7.14 Share Price '28

Discounted to 2025 @ 6.98% p.a.

US$5.83

Fair Value '25